Triple-negative breast cancer: current perspective on the evolving therapeutic landscape.
PARP inhibitors
breast cancer
immunotherapy
triple-negative
Journal
International journal of women's health
ISSN: 1179-1411
Titre abrégé: Int J Womens Health
Pays: New Zealand
ID NLM: 101531698
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
03
2019
accepted:
09
07
2019
entrez:
27
8
2019
pubmed:
27
8
2019
medline:
27
8
2019
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.
Identifiants
pubmed: 31447592
doi: 10.2147/IJWH.S178349
pii: 178349
pmc: PMC6682754
doi:
Types de publication
Journal Article
Langues
eng
Pagination
431-437Déclaration de conflit d'intérêts
Matteo Lambertini served as a consultant for Teva and received honoraria from Theramex and Takeda outside the submitted work. All remaining authors declared no conflicts of interest in this work.
Références
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Breast Cancer Res. 2009;11(4):R47
pubmed: 19589159
Eur J Cancer. 2009 Sep;45 Suppl 1:27-40
pubmed: 19775602
Clin Cancer Res. 2009 Dec 1;15(23):7277-90
pubmed: 19934293
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Breast Dis. 2010;32(1-2):25-33
pubmed: 21778580
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
BMC Med. 2015 Aug 13;13:188
pubmed: 26268938
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
J Clin Oncol. 2016 Nov 1;34(31):3803-3815
pubmed: 27621407
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Breast Care (Basel). 2017 Mar;12(1):8-14
pubmed: 28611535
Breast. 2017 Oct;35:142-150
pubmed: 28735162
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861
J Clin Oncol. 2018 Mar 20;36(9):884-890
pubmed: 29373071
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
Ann Oncol. 2018 Jul 1;29(7):1497-1508
pubmed: 29873695
ESMO Open. 2018 Jun 20;3(4):e000361
pubmed: 29942664
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Ann Oncol. 2018 Sep 1;29(9):1939-1947
pubmed: 30124753
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
Lancet. 2019 Apr 6;393(10179):1440-1452
pubmed: 30739743
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Ther Adv Med Oncol. 2019 Feb 25;11:1758835919827714
pubmed: 30833989
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061